Ghrelin-induced stimulation of colonic propulsion is dependent on hypothalamic neuropeptide Y1- and corticotrophin-releasing factor 1 receptor activation.
Peptides participating in the hypothalamic control of feeding behaviour are also involved in the central autonomic control of gastrointestinal functions, such as secretion and motility. An anatomical interaction and functional relationship in the central nervous system between the feeding-related peptides neuropeptide Y and ghrelin is well documented. Furthermore, it has been shown that feeding-related peptides can influence digestive function via central corticotrophin-releasing factor (CRF) pathways. In the present study, we investigated the role of ghrelin in the central autonomic control of colonic motility. Furthermore, we addressed the hypothesis that ghrelin is involved in the hypothalamic control of colonic motor function, utilizing central neuropeptide Y receptors and hypothalamic CRF pathways. Ghrelin (0.03, 0.06 and 0.12 nmol) bilaterally microinjected into the paraventricular nucleus (PVN) induced a significant stimulation of colonic propulsion. In particular, the colonic transit time decreased from 312+/-7 min to 198+/-12 min. Microinjection of the neuropeptide Y1 receptor antagonist, BIBP-3226 (200 pmol), or the nonselective CRF receptor antagonist, astressin (30 pmol), into the PVN abolished the stimulatory effect of ghrelin injected into the PVN on colonic transit time, whereas pretreatment with the selective CRF2 receptor, antisauvagine-30 (28 pmol), failed to affect the effect of PVN-ghrelin injection on colonic propulsion. These results suggest that ghrelin can act as central modulator of gastrointestinal motor functions at the level of the PVN via neuropeptide Y1- and CRF1 receptor-dependent mechanisms.
Tebbe
J J
JJ
Department of Internal Medicine, Division of Gastroenterology and Endocrinology, Philipps Universität Marburg, Marburg, Germany. tebbe@staff.uni-marburg,de
Mronga
S
S
Tebbe
C G
CG
Ortmann
E
E
Arnold
R
R
Schäfer
M K-H
MK
D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D001921:Brain / Q000033:anatomy & histology; D003106:Colon / Q000187:drug effects* / Q000294:innervation; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology; D005769:Gastrointestinal Motility / Q000187:drug effects*; D054439:Ghrelin; D007031:Hypothalamus / Q000378:metabolism / Q000502:physiology*; D008297:Male; D008845:Microinjections; D009478:Neuropeptide Y / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000378:metabolism; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D036361:Peptide Hormones / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013268:Stimulation, Chemical; D000099052:CRF Receptor, Type 1
C092926:BIBP 3226; D054439:Ghrelin; D009478:Neuropeptide Y; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D036361:Peptide Hormones; D018019:Receptors, Corticotropin-Releasing Hormone; C116607:antisauvagine 30; C104416:astressin; D000099052:CRF Receptor, Type 1; D003346:Corticotropin-Releasing Hormone; D001120:Arginine